These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
17. EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors. Karres D, Ali S, van Hennik PB, Straus S, Josephson F, Thole G, Glerum PJ, Herberts C, Babae N, Herold R, Papadouli I, Pignatti F. Oncologist; 2020 Jun; 25(6):e976-e981. PubMed ID: 32154610 [Abstract] [Full Text] [Related]
18. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis. Laszlo D, Marcacci GP, Martino M, Radice D, Rabascio C, Lucchetti B, Magarò A, Caime A, Menna S, Lionetti MT, Bertolini F. Transfus Apher Sci; 2020 Oct; 59(5):102819. PubMed ID: 32499108 [Abstract] [Full Text] [Related]
19. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma. Lor KW, Helmons PJ, Belew H, Lane JR, Ball ED. Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691 [Abstract] [Full Text] [Related]